Track market-moving stories before they get noisy

Key Takeaways Omnicell reports Q2 2026 results on July 30, with revenues seen rising 6.6% and EPS expected to grow 6.7%. OMCL may benefit from OmniSphere adoption, customer wins and Titan XT traction across health systems. Omnicell's Product and Services revenue growth is expected to reflect demand and recurring software momentum. Omnicell (OMCL - Free Report) is set to release second-quarter 2026 results on July 30, before market open. 

In the last reported quarter, the company posted adjusted earnings per share (EPS) of 55 cents, which surpassed the Zacks Consensus Estimate by 66.67%. Omnicell beat on earnings in three of the trailing four quarters and missed on one occasion, the average surprise being 34.65%.

OMCL’s Q2 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $309.6 million, which suggests 6.6% growth from the year-ago reported figure.

The Zacks Consensus Estimate for earnings is pinned at 48 cents per share, which implies a 6.7% rise from the year-ago recorded actuals.

Estimate Revision Trend Ahead of OMCL’s Q2 EarningsEstimates for second-quarter earnings have remained unchanged at 48 cents per share in the past 30 days.

Here’s a brief overview of the company’s performance leading up to this announcement.

Factors Shaping OMCL’s Q2 PerformanceThe company is expected to have delivered another quarter of solid growth, supported by continued execution of its Connected Devices strategy and expanding recurring revenue streams. Demand is likely to have remained strong across inpatient and outpatient pharmacies as well as broader patient care settings, reflecting continued adoption of Omnicell's medication management solutions. 

Second-quarter revenue growth is also expected to have been supported by increasing penetration of OmniSphere, a cloud-native medication management platform, as healthcare providers continue to prioritize enterprise-wide automation, workflow optimization and data-driven medication management. 

The second-quarter top line is also likely to have benefited from continued customer wins among large and complex health systems. The recently launched Titan XT next-generation automated dispensing system is expected to have gained further commercial traction, supported by its integration with the OmniSphere platform. The combined offering is likely to have strengthened Omnicell's value proposition by providing enterprise-wide visibility, guided clinical workflows and a modern cloud-based infrastructure designed for large healthcare organizations.

From a segment perspective, Product revenues are expected to have benefited from sustained demand for the Connected Devices portfolio across both North America and international markets, supported by ongoing capital investments from healthcare providers.

The Zacks Consensus Estimate for Product revenues indicates 5.2% year-over-year growth for the second quarter. 

Service revenues are likely to have remained on a growth trajectory, supported by higher recurring software and service revenues, including continued momentum in Specialty Pharmacy Services. This growth is expected to have been driven by increasing customer adoption of subscription-based and technology-enabled medication management solutions.

The Zacks Consensus Estimate for Services revenues indicates 5% year-over-year growth for the second quarter. 

Omnicell, Inc. Price and EPS SurpriseWhat Our Quantitative Model Predicts for OMCLPer our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. However, this is not the case here, as you can see below:

Earnings ESP: Omnicell has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.

Top MedTech PicksHere are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:

Hinge Health Inc. (HNGE - Free Report) has an Earnings ESP of +4.24% and a Zacks Rank #1 at present. The company is expected to release second-quarter 2026 results soon.

In the trailing four quarters, HINGE delivered an average earnings surprise of 179.54%. The Zacks Consensus Estimate for second-quarter EPS implies a decrease of 11.9% from the year-ago quarter’s figure.

Neurocrine Biosciences (NBIX - Free Report) has an Earnings ESP of +40.60% and a Zacks Rank #1 at present. The company is expected to release second-quarter 2026 results soon.

NBIX’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 9.08%. The Zacks Consensus Estimate for the company’s second-quarter EPS calls for an increase of 112.3% from the year-ago quarter’s figure.

West Pharmaceutical Services (WST - Free Report) has an Earnings ESP of +1.09% and a Zacks Rank #2 at present. The company is slated to release second-quarter 2026 results on July 23. 

WST’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.37%. The Zacks Consensus Estimate for WST’s second-quarter EPS implies a rise of 13% from the year-ago reported figure.

Key Takeaways Omnicell is expanding autonomous pharmacy solutions with SaaS, services and OmniSphere adoption.OMCL is benefiting from health system wins, international expansion and recurring subscription revenue.Omnicell expects tariff costs in 2026, while labor shortages and inflation remain operational challenges. Shares of Omnicell (OMCL - Free Report) have rallied 52.6% over the past year, significantly outperforming the industry’s 20.8% fall and the S&P 500 composite’s 23.9% gain.

Sporting a Zacks Rank #1 (Strong Buy) at present, the healthcare technology company continues to pursue the vision of the autonomous pharmacy, designed to improve medication management outcomes. Growth in SaaS and Expert Services, rising adoption among health systems and international expansion further strengthen its outlook.

Headquartered in Mountain View, CA, Omnicell develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application and a Web-based procurement application. The products offered by the company enable care providers to improve patient safety and increase efficiency by lowering costs.

Factors Favoring OMCL’s GrowthOmnicell continues to advance toward its goal of achieving the industry-defined vision of autonomous medication management, which is a roadmap to improving operational efficiencies and ultimately targeting zero-error medication management. Over the past several years, Omnicell has evolved from offering a single-point solution to a platform of products and services and has also secured several wins with major health systems and government health care facilities. OMCL’s ongoing R&D investments across Points of Care, Central Pharmacy and IV Compounding, Specialty Pharmacy and 340B Program and Ambulatory Care market categories are expected to deliver solutions that drive positive medication management outcomes for customers.

Image Source: Zacks Investment Research

The company derives an increasing portion of revenues from its subscription-based SaaS and Expert Services offerings, which include a combination of robotics, smart devices and intelligent software, all optimized by expert services. In recent years, Omnicell has integrated three key acquisitions, such as Specialty Pharmacy Services (formerly ReCept), FDS Amplicare and MarkeTouch Media, LL (merged into EnlivenHealth, Inc), to broaden the offerings. In 2025, SaaS and Expert Services revenues were $259 million.

In the first quarter of 2026, several health systems committed to using Omnicell's inventory optimization service, alongside central pharmacy automation and point-of-care dispensing solutions. The company announced OmniSphere in late 2024, a cloud-native platform designed to unify all Omnicell products under a single, secure infrastructure to make it simpler, safer and more connected to manage medications within a growing health system. EnlivenHealth also continues to gain traction with cross-selling and upselling communication solutions to existing customers.

Healthcare providers outside the United States are becoming increasingly aware of the benefits of automation. There is a substantial demand for adherence packaging equipment outside the domestic market. Omnicell’s international operations include its sales efforts centered in Canada, Europe, the Middle East and the Asia-Pacific regions and supply-chain efforts in Asia. Given the fact that the international market is less than 1% penetrated, with very few hospitals adopting medication control systems, this creates a solid long-term growth opportunity.

Risks for OMCLSimilar to its health-care system partners, Omnicell’s operations continue to be affected by persisting labor shortages as well as increased inflationary costs related to components’ raw materials and freight. The company’s 2026 guidance incorporates an updated estimate of approximately $12 million in tariff-related costs impacting profitability.  

A Glance at OMCL’s EstimatesThe Zacks Consensus Estimate for Omnicell's earnings per share (EPS) is pegged at $1.97 for 2026 and $2.23 for 2027, implying year-over-year growth of 21.6% and 13.2%, respectively. Over the past 60 days, the consensus estimate for 2026 EPS has moved up 5.3%, while the 2027 estimate has increased 2.3%.

Revenues for 2026 are projected to grow 4.9% to $1.24 billion, and another 4.2% to $1.30 billion in 2027.

Other Key StocksSome other top-ranked stocks in the broader medical space are Illumina (ILMN - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .

Illumina has an earnings yield of 2.8% compared to the industry’s negative 14.6% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 12.2%. ILMN shares have rallied 95.8% compared with the industry’s 25.6% growth over the past year.

ILMN carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Align Technology, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 5.5% growth. Shares of the company have dipped 6.3% against the industry’s 9.6% growth. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.

Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 13.7% against the industry’s negative 3% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 33.8% against the industry’s 10.5% decline over the past year.